What is InClin?
InClin operates as a full-service Contract Research Organization (CRO), offering a comprehensive suite of services that span strategic consulting, clinical operations, biometrics, and medical writing. With a global presence, including offices in San Mateo, California, and Sydney, Australia, InClin collaborates with pharmaceutical and biotechnology firms to advance clinical trials from early-stage Phase 1 through late-stage Phase 4. The organization is committed to enhancing patient outcomes by supporting the development of novel therapies across a spectrum of diseases. InClin's seasoned professionals are adept at managing complex clinical trial processes, delivering bespoke solutions designed to meet the specific requirements of their clientele.
How much funding has InClin raised?
InClin has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
What's next for InClin?
The substantial enterprise-level backing InClin has received positions it for accelerated scaling and market penetration. This significant capital infusion is likely to fuel strategic initiatives, including the expansion of its service offerings, enhancement of its technological infrastructure, and broadening of its geographical reach. As a key player in the CRO space, InClin is poised to capitalize on the increasing demand for specialized clinical trial support, particularly as the pharmaceutical industry continues to invest heavily in research and development. The company's focus on innovation and quality in clinical trial management suggests a strategic direction aimed at solidifying its leadership position and driving the successful development of new therapeutic agents.
See full InClin company page
